SkinHealth Systems Inc. SKIN
Nov 4, 2026, 2:14 PM EST
- YTD
- +700.72%
- 1 year
- +706.52%
- Market cap
- 72.38M
- Revenue (ttm)
- 347.62M
- Profit margin
- -8.10%
- EPS (ttm)
- -4.60
- Shares out
- 124.12M
- Forward P/E
- -9.00
- YTD return
- +700.72%
- 1-year return
- +706.52%
- Volume
- 25.25K
- Avg volume
- 26.85K
- Open
- 10.44
- Previous close
- 10.35
- Day's range
- 10.15 – 11.21
- 52-week range
- 9.68 – 34.80
- Beta
- 0.91
- Analysts
- Hold
- Price target
- 1.72 (-84.6%)
- Earnings date
- Aug 8, 2024
2Y +9.50 (+590.06%)
Key statistics
- Enterprise value
- 390.66M
- PEG ratio
- 0.00
- Price / sales
- 0.51
- Price / book
- 2.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -19.10%
- Free cash flow
- -375.50K
- Total cash
- 358.89M
- Total debt
- 568.33M
- Return on equity
- -37.64%
- Short % of float
- 16.11%
- 50-day average
- 1.58
- 200-day average
- 2.17
Analyst view
Consensus: hold
- Target (low)
- 1.00
- Target (mean)
- 1.72
- Target (high)
- 2.00
- Strong buy0
- Buy0
- Hold7
- Sell0
- Strong sell3
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.12 | -0.15 | -0.03 | -25.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.05 | -0.10 | -0.05 | -100.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.05 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.14 | -0.10 | +0.04 | +28.57% |
| May 9, 2024 | Mar 1, 2024 | -0.14 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | -0.11 | -0.07 | +0.04 | +36.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | Canaccord Genuity | main | Hold | Hold |
| Aug 12, 2024 | Canaccord Genuity | main | Hold | Hold |
| Aug 9, 2024 | Piper Sandler | reit | Underweight | Underweight |
| Jul 26, 2024 | Stifel | main | Hold | Hold |
| Jul 11, 2024 | Piper Sandler | main | Underweight | Underweight |
| May 13, 2024 | DA Davidson | main | Buy | Buy |
About SkinHealth Systems Inc.
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Country
- United States
- Website
- beautyhealth.com
News
SkinHealth Systems Inc. (SKIN) Expected to Beat Earnings Estimates: Should You Buy? 
SkinHealth Systems to Report Third Quarter 2026 Financial Results on November 5, 2026 
SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? 
Full Transcript: Beauty Health Q2 2026 Earnings Call 
Niagen Bioscience (NASDAQ:NAGE) and Beauty Health (NASDAQ:SKIN) Head to Head Review 
SkinHealth Systems Announces Reverse Stock Split 
e.l.f. SKIN's Save Your e.l.f. Hypochlorous Mist Helps Soothe Stress in every e.l.f.ing mist-mergency 
Hydrafacial Introduces HydraClear™ Treatment Booster to Clarify Blemish-Prone Skin 
Contrasting Beauty Health (NASDAQ:SKIN) and Betterware de Mexico SAPI de C (NYSE:BWMX) 
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
Your note
Sign in to keep a note on SKIN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BECK MARLA MALCOLM | Chief Executive Officer | Stock Award(Grant) | Apr 8, 2024 | 1,078,210 |
| CAPELLAS MICHAEL D | Director | Stock Award(Grant) | Jul 7, 2024 | 276,146 |
| FEW JULIUS | Director | Stock Award(Grant) | Jul 7, 2024 | 194,341 |
| GRUBER DESIREE | Director | Sale | Nov 19, 2024 | 119,514 |
| KERRICK MICHELLE C. | Director | Stock Award(Grant) | Jul 7, 2024 | 116,762 |
| MILLER BRIAN CHRISTOPHER | Director | Stock Award(Grant) | Jul 7, 2024 | 169,984 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.99% | 18,603,037 | 26.79M | Sep 29, 2024 |
| Janus Henderson Group PLC | 9.03% | 11,209,408 | 16.14M | Sep 29, 2024 |
| Blackrock Inc. | 4.53% | 5,620,752 | 8.09M | Sep 29, 2024 |
| Vanguard Group Inc | 4.46% | 5,536,433 | 7.97M | Sep 29, 2024 |
| Braidwell LP | 3.26% | 4,049,694 | 5.83M | Sep 29, 2024 |
| Jacobs Levy Equity Management, Inc. | 2.01% | 2,499,652 | 3.60M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Contrarian Fund | 8.96% | 11,117,965 | 16.01M | Sep 29, 2024 |
| Fidelity Growth Company Fund | 3.10% | 3,848,924 | 5.54M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.17% | 2,698,071 | 3.89M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.59% | 1,979,456 | 2.85M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 1.15% | 1,430,456 | 2.06M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.02% | 1,266,061 | 1.82M | Sep 29, 2024 |